Teva Reports Second Quarter 2014 Results
Revenues of $5.0 billion, up 2% compared to the second quarter of 2013.
Non GAAP operating income of $1.4 billion, an increase of 8%. GAAP operating income of $925 million.
Non-GAAP net income of $1.05 billion, an increase of 4%. GAAP net income of $748 million.
Non-GAAP diluted EPS of $1.23, an increase of 3%. GAAP diluted EPS of $0.87.
Strong cash flow from operations of $1.25 billion, an increase of 43%, excluding the effect of payment related to legal settlements.
Generic medicine revenues up 5%, with U.S. generics sales up 10% and generic medicine profitability up 41%.
More than half of Copaxone® prescriptions in the U.S. today are for Copaxone® 40mg/mL.
EPS guidance for 2014 improved to $4.90-5.10 in the exclusive Copaxone® scenario, and to $4.50-4.80 in the generic Copaxone® scenario.
JERUSALEM--(BUSINESS WIRE)--Jul. 31, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today reported results for the quarter ended June 30, 2014.
"We are pleased with the results of the second quarter of 2014, delivering organic growth in revenues and all profit lines over the comparable quarter last year. Our generic business delivered solid results with significantly improved profitability. In our specialty business, we have successfully converted, to date, 51% of the Copaxone® family in the U.S. to the newly-launched Copaxone® 40mg/mL, and are continuing to stably lead the global and U.S. relapsing remitting multiple sclerosis market. We are also excited about the progress we are making in our specialty pipeline, which includes, this quarter, the successful launch of DuoResp Spiromax® in Europe, the progression toward FDA submission for ER hydrocodone and the FDA acceptance of our albuterol MDPI NDA," stated Erez Vigodman, President and CEO of Teva.
Mr. Vigodman continued, "We are also making significant progress on our top priorities for 2014: solidifying the foundation of Teva, maintaining the Copaxone® franchise, driving organic growth and positioning Teva for long-term value creation. This quarter, we have announced a new organizational structure for Teva, including the formation of the Global Generics Medicines group under the leadership of Siggi Olafsson, one of the most experienced executives in the generic industry. We continued to accelerate the transformation of our operational network, and have performed a thorough review of our cost reduction program, which yielded additional net savings. We have also acquired Labrys, adding an important asset to our unique patient-centric offering in the pain area. Finally, we are progressing in defining and shaping the future strategic direction of Teva."
Generic Medicine Segment
Generics
Three Months Ended June 30,
2014 2013
U.S.$ in millions / % of Segment Revenues
Revenues $ 2,515 100.0% $ 2,405 100.0%
Gross profit 1,046 41.6% 989 41.1%
R&D expenses 126 5.0% 124 5.2%
S&M expenses 388 15.4% 489 20.3%
Segment profitability* $ 532 21.2% $ 376 15.6%
* Segment profitability consists of gross profit, less S&M and R&D expenses related to the segment.
Segment profitability does not include G&A expenses, amortization and certain other items.
We recently changed the classification of certain of our products. The data presented have been
conformed to reflect the revised classification for all periods.
Generic medicine revenues in the second quarter of 2014 amounted to $2.5 billion (including API sales of $182 million), an increase of 5% in both U.S. dollar and local currency terms, compared to the second quarter of 2013.
Generic revenues consisted of:
U.S. revenues of $1.1 billion, an increase of 10% compared to the second quarter of 2013. The increase resulted mainly from a full quarter of sales of capecitabine (the generic equivalent of Xeloda®) which was launched exclusively in March of 2014 and the launch of omega-3-acid ethyl esters (the generic equivalent of Lovaza®) for which we were first to market, as well as sales of products that were sold in the second quarter of 2014 but not sold in the second quarter of 2013, the most significant of which were raloxifene (the generic equivalent of Evista®) and tolterodine tartrate (the generic equivalent of Detrol®). These increases were partially offset by declines in other products due to loss of exclusivity or additional competition, the most significant of which was amphetamine salts (the generic equivalent of Adderall®).
European revenues of $814 million, a decrease of 2%, or 6% in local currency terms, compared to the second quarter of 2013. The decrease in revenues resulted mainly from our strategy of pursuing profitable and sustainable business in the region and taking a selective approach to the tender market, resulting in a notable improvement in the profitability of our European generics business.
ROW revenues of $633 million, an increase of 4%, or 11% in local currency terms, compared to the second quarter of 2013. The increase in local currency terms was driven by higher revenues in Canada, due to the reversal of a pricing reserve for a product sold in previous years, and in Latin America. Our ROW markets were impacted significantly by the weakening of various local currencies compared to the U.S. dollar.
API sales to third parties in the second quarter of 2014 amounted to $182 million, a decrease of 4%, or of 5% in local currency terms, compared to the second quarter of 2013. The decrease resulted from lower sales mainly in our ROW markets and in the United States.
Generic medicine revenues comprised 50% of our total revenues in the quarter, up from 49% in the second quarter of 2013.
Generic Medicine Gross Profit
Gross profit from our generic medicine segment in the second quarter of 2014 amounted to $1.0 billion, an increase of $57 million, or 6%, compared to the second quarter of 2013. Gross profit margin for our generic medicine segment in the second quarter of 2014 increased to 41.6%, from 41.1% in the second quarter of 2013. The higher gross profit was mainly a result of higher revenues in the United States and Canada, and higher gross profit due to the change in the composition of revenues in Europe, as well as the impact of our efficiency measures.
Generic Medicine Profitability
Profitability of our generic medicine segment amounted to $532 million in the second quarter of 2014, compared to $376 million in the second quarter of 2013. Generic medicine profitability as a percentage of generic medicine revenues was 21.2% in the second quarter of 2014, up from 15.6% in the second quarter of 2013. The increase was primarily due to a reduction in S&M expenses, higher revenues and higher gross profit.
Specialty Medicine Segment
Specialty
Three Months Ended June 30,
2014 2013
U.S.$ in millions / % of Segment Revenues
Revenues $ 2,027 100% $ 2,051 100%
Gross profit 1,768 87.2% 1,772 86.4%
R&D expenses 214 10.6% 208 10.1%
S&M expenses 484 23.9% 450 21.9%
Segment profitability* $ 1,070 52.8% $ 1,114 54.3%
* Segment profitability consists of gross profit, less S&M and R&D expenses related to the segment.
Segment profitability does not include G&A expenses, amortization and certain other items.
We recently changed the classification of certain of our products. The data presented have been
conformed to reflect the revised classification for all periods.
Specialty medicine revenues in the second quarter of 2014 amounted to $2.0 billion, a decrease of 1% compared to the second quarter of 2013. U.S. specialty medicine revenues amounted to $1.4 billion, a decrease of 5% compared to the second quarter of 2013. European specialty medicine revenues amounted to $501 million, an increase of 13%, or 7% in local currency terms, compared to the second quarter of 2013. ROW specialty medicine revenues amounted to $107 million, a decrease of 4%. In local currency terms, revenues increased 5% compared to the second quarter of 2013.
Specialty medicine revenues comprised 40% of our total revenues in the quarter, down from 42% in the second quarter of 2013.
The decrease in specialty medicine revenues from the second quarter of 2013 was primarily due to lower sales of Copaxone® in the U.S., which were largely offset by higher revenues from sales of specialty medicines in Europe.
The following table presents revenues by therapeutic area and key products for our specialty medicine segment for the three months ended June 30, 2014 and 2013:
Specialty Medicine Revenues Breakdown
Three Months Ended
June 30,
Percentage
Change
2014 2013 2014 - 2013
U.S. $ in millions
CNS $ 1,271 $ 1,361 (7%)
Copaxone® 939 1,070 (12%)
Azilect® 103 87 18%
Nuvigil® 88 74 19%
Oncology 284 246 15%
Treanda® 190 177 7%
Respiratory 257 241 7%
ProAir® 133 115 16%
Qvar® 74 76 (3%)
Women's Health 128 118 8%
Other Branded 87 85 2%
Total Specialty Medicines $ 2,027 $ 2,051 (1%)
We recently changed the classification of certain of our products. The data presented have been
conformed to reflect the revised classification for all periods.
Global sales of Copaxone® (20 mg/mL and 40 mg/mL), the leading multiple sclerosis therapy in the U.S. and globally, amounted to $0.9 billion, a decrease of 12% compared to the second quarter of 2013. In the United States, sales decreased 19% to $662 million. The decrease in the U.S. was mainly due to lower volume, partially offset by a price increase of 9.9% in January 2014 on Copaxone® 20 mg/mL. Our sales during the quarter were affected by higher levels of inventory created in the previous quarter following the launch of Copaxone® 40 mg/mL due to uncertainty of the prospective conversion rate between two products, as well as customers reducing inventory of the Copaxone® 20 mg/mL due to potential risk of a competing generic launch.
At the end of the second quarter of 2014, according to June 2014 IMS data, our U.S. market shares for the Copaxone® products in terms of new and total prescriptions were 32.2% and 33.2%, respectively. Copaxone® 40 mg/mL U.S. market shares in terms of new and total prescriptions were 17.3% and 15.1%, respectively, such that Copaxone® 40 mg/mL accounted for 45% of total Copaxone® prescriptions.
Sales outside the United States amounted to $277 million, an increase of 9%, or of 8% in local currency terms, compared to the second quarter of 2013. The increase is a result of lower mandatory rebates and higher demand in certain European markets.
Our global Azilect® revenues amounted to $103 million, an increase of 18% compared to the second quarter of 2013, while global in-market revenues increased 14% to $136 million. The increase in our sales reflects volume growth and price increases in the United States, as well as volume growth in Europe.
Sales of our oncology products amounted to $284 million in the second quarter of 2014, an increase of 15% compared to the second quarter of 2013. The increase resulted primarily from sales of our recently launched G-CSF products, Lonquex® and Granix®. Sales of Treanda® amounted to $190 million in the second quarter of 2014, compared to $177 million in the second quarter of 2013.
Sales of our respiratory products amounted to $257 million in the second quarter of 2014, an increase of 7% compared to the second quarter of 2013. ProAir® revenues amounted to $133 million in the second quarter of 2014, an increase of 16% compared to the second quarter of 2013, mainly due to volume growth as well as price fluctuations. Qvar® revenues amounted to $74 million in the second quarter of 2014, a decrease of 3% compared to the second quarter of 2013, due to price fluctuations. Following an April approval from the EMA, DuoResp Spiromax® for the treatment of asthma and COPD, was launched in Germany and Denmark in May and in Portugal in June.
Specialty Medicine Gross Profit
Gross profit from our specialty medicine segment amounted to $1.8 billion in the second quarter of 2014, in line with the second quarter of 2013.
Gross profit margin for our specialty medicine segment in the second quarter of 2014 was 87.2%, compared to 86.4% in the second quarter of 2013. The increase in gross margin was a result of the different product mix.
Specialty Medicine Profitability
Profitability of our specialty medicine segment amounted to $1.1 billion in the second quarter of 2014, a decrease of 4% compared to the second quarter of 2013, mainly due to higher S&M expenses in connection with new product launches.
Specialty medicine profitability as a percentage of segment revenues was 52.8% in the second quarter of 2014, down from 54.3% in the second quarter of 2013.
The following tables present details of our multiple sclerosis franchise and of our other specialty medicines for the three months ended June 30, 2014 and 2013:
Multiple Sclerosis
Three months ended June 30,
2014 2013
U.S.$ in millions / % of MS Revenues
Revenues 939 100.0% 1,070 100.0%
Gross profit 840 89.5% 951 88.9%
R&D expenses 20 2.1% 20 1.9%
S&M expenses 120 12.8% 130 12.1%
MS profitability 700 74.5% 801 74.9%
Other Specialty
Three months ended June 30,
2014 2013
U.S.$ in millions / % of Other Specialty Revenues
Revenues 1,088 100.0% 981 100.0%
Gross profit 928 85.3% 821 83.7%
R&D expenses 194 17.8% 188 19.2%
S&M expenses 364 33.5% 320 32.6%
Other Specialty profitability 370 34.0% 313 31.9%
We recently changed the classification of certain of our products. The data presented have
been conformed to reflect the revised classification for all periods.
Other Activities
OTC revenues amounted to $274 million in the second quarter of 2014, an increase of 7% in both U.S. dollar and local currency terms, compared to the second quarter of 2013, primarily due to higher sales in Europe.
PGT's in-market sales amounted to $350 million in the second quarter of 2014, an increase of $8 million compared to the second quarter of 2013. This increase was due to higher sales in Europe, partially offset by lower sales in Latin America and Asia.
Revenues from the sales of OTC products in the United States to P&G amounted to $48 million in the second quarter of 2014, compared to $55 million in the second quarter of 2013.
In July 2014, we sold our two U.S. OTC plants previously purchased from P&G back to P&G, in exchange for a 49% interest in New Chapter, Inc., which was previously fully owned by P&G. These plants produced substantially all of the OTC products sold to P&G in the United States. Consequently, we will no longer sell OTC products to P&G from those plants.
Other revenues amounted to $229 million in the second quarter of 2014, mostly from the distribution of third-party products in Israel and Hungary, compared to $211 million in the second quarter of 2013.
Key Metrics for the Second quarter 2014
Non-GAAP information: Net non-GAAP charges in the second quarter of 2014 amounted to $306 million, consisting mainly of amortization of purchased intangible assets. Accordingly, non-GAAP net income and non-GAAP EPS for the quarter are adjusted to exclude these and certain other items, as follows:
Amortization of purchased intangible assets totaling $256 million, of which $249 million is included in cost of goods sold and the remaining $7 million in selling and marketing expenses;
Restructuring, impairment and other expenses of $148 million;
Legal settlements of $26 million;
Regulatory actions taken in facilities of $14 million; and
Related tax benefit of $138 million.
Teva believes that excluding such items facilitates investors' understanding of its business. See the attached tables for a reconciliation of the U.S. GAAP results to the adjusted non-GAAP figures.
Exchange rate differences between the second quarter of 2014 and the second quarter of 2013 increased our revenues by $16 million but reduced our non-GAAP operating income by $16 million.
Non-GAAP gross profit was $2.9 billion in the second quarter of 2014, in line with results in the second quarter of 2013. Non-GAAP gross profit margin was 58.0% in the second quarter of 2014, compared to 58.7% in the second quarter of 2013. GAAP gross profit was $2.7 billion in the second quarter of 2014, compared to $2.6 billion in the second quarter of 2013. GAAP gross profit margin was 52.7% in the quarter, in line with the second quarter of 2013.
Research & Development (R&D) expenditures (excluding purchase of in-process R&D) in the second quarter of 2014 amounted to $344 million, compared to $336 million, in the second quarter of 2013. R&D expenses were 6.8% of revenues in both quarters. R&D expenses related to our generic medicine segment amounted to $126 million in the second quarter of 2014, an increase of 2% compared to $124 million in the second quarter of 2013, mainly due to higher expenses associated with the generic medicine segment in the United States. R&D expenses related to our specialty medicine segment amounted to $214 million in the second quarter of 2014, an increase of 3% compared to $208 million in the second quarter of 2013, primarily as a result of increased investment in our specialty pipeline.
Selling and Marketing (S&M) expenditures (excluding amortization of purchased intangible assets) amounted to $914 million, or 18.1% of revenues, in the second quarter of 2014, compared to $973 million, or 19.8% of revenues in the second quarter of 2013. S&M expenses related to our generic medicine segment amounted to $388 million in the second quarter of 2014, a decrease of 21% compared to $489 million in the second quarter of 2013, mainly due to lower expenses in Europe and in Russia and lower royalty expenses in the United States. S&M expenses related to our specialty medicine segment amounted to amounted to $484 million, an increase of 8% compared to $450 million in the second quarter of 2013. The increase was primarily due to higher expenditures related to our launches of DuoResp Spiromax®, Lonquex®, Granix® and Adasuve®, as well as preparation for additional product launches planned for the remainder of 2014.
General and Administrative (G&A) expenditures amounted to $302 million in the second quarter of 2014, or 6.0% of revenues, compared with $319 million, or 6.5% of revenues, in the second quarter of 2013. The decrease in G&A expenses was mainly due to other income related to a legal recovery in Canada and lower expenses related to our joint venture with P&G, partially offset by an increase in other expenses.
Quarterly non-GAAP operating income was $1.4 billion in the second quarter of 2014, an increase of 8% compared to the second quarter of 2013. Quarterly GAAP operating income was $925 million in the second quarter of 2014, compared to a loss of $586 million in the second quarter of 2013.
Non-GAAP financial expenses amounted to $76 million in the second quarter of 2014, compared to $82 million in the second quarter of 2013. GAAP financial expenses for the second quarter of 2014 amounted to $78 million, compared to $89 in the second quarter of 2013.
The provision for non-GAAP tax for the second quarter of 2014 amounted to $240 million on pre-tax non-GAAP income of $1.3 billion, for a quarterly tax rate of 18.6%. The provision for tax in the second quarter of 2013 was $161 million on pre-tax income of $1.2 billion, or 13.7%. GAAP tax expenses for the second quarter of 2014 amounted to $102 million on pre-tax income of $847 million, for a quarterly GAAP tax rate of 12.0%. In the second quarter of 2013, tax benefits amounted to $222 million on pre-tax loss of $675 million.
The increase in our quarterly tax rate mainly reflects the lapse of our tax exemptions under the previous Israeli tax incentives regime in 2013. Our profits in Israel are now generally subject to tax at 9%.
GAAP net income and GAAP diluted EPS were $748 million and $0.87 in the second quarter of 2014, compared to a loss of $452 million and a loss per share of $0.53 in the second quarter of 2013. Non-GAAP net income and non-GAAP diluted EPS were $1.05 billion and $1.23 in the second quarter of 2014, an increase of 4% and 3%, respectively, compared to $1.02 billion and $1.20 in the second quarter of 2013.
Cash flow from operations generated during the second quarter of 2014 amounted to $1.1 billion, compared to $0.9 billion in the second quarter of 2013, mainly due to the increase in net income and the improvement in working capital. Free cash flow, excluding net capital expenditures and dividends amounted to $583 million, an increase of $205 million from the second quarter of 2013.
Cash and marketable securities at June 30, 2014 amounted to $1.2 billion.
For the second quarter of 2014, the weighted average outstanding shares for the fully diluted earnings per share calculation was 857 million on both a GAAP and non-GAAP basis. At June 30, 2014, the outstanding shares for calculating Teva's market capitalization were approximately 853 million.
Shareholders' equity was $23.6 billion at June 30, 2014, compared to $23.0 billion at March 31, 2014. The increase primarily reflects GAAP net income of $0.75 billion and proceeds from employee stock option exercises of $0.1 billion, partially offset by dividend payments of $0.3 billion.
Dividend
The Board of Directors, at its meeting on July 29, 2014, declared a cash dividend for the second quarter of 2014 of NIS 1.21 per share (approximately 35.3 cents according to the rate of exchange on July 29, 2014).
The record date will be August 21, 2014, and the payment date will be September 4, 2014. Tax will be withheld at a rate of 15%.
Conference Call
Teva will host a live webcast and a conference call to discuss its second quarter 2014 results on Thursday, July 31, 2014, at 8:00 a.m. ET. To access the live webcast and view the accompanying slide presentation, visit the Investor Relations section of Teva's website, at http://ir.tevapharm.com, at least 15 minutes before the presentation is scheduled to begin; click on the webcast icon to register and download or install any necessary software. In addition to the webcast, the call can be accessed by dialing in to the following numbers, at least ten minutes prior to the scheduled call time: United States 1-866-904-9433; Canada 1-866-361-5782; international +44(0)1452-580111; passcode: 65239352#.
Following the conclusion of the call, a replay of the webcast will be available within 24 hours at the Company's website at www.tevapharm.com. A replay of the call will also be available until August 8, 2014, at 11:00 a.m. ET, by calling: United States 1-866-247-4222; Canada 1-866-878-9237 or international +44(0)1452-550000; passcode: 65239352#.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients.
Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules, sold in more than 100 countries, and with a direct presence in about 60 countries. Teva's specialty medicine businesses focus on CNS, including pain, respiratory, oncology, and women's health therapeutic areas as well as biologics. Teva currently employs approximately 45,000 people around the world and reached $20.3 billion in net revenues in 2013.
Teva's Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products; competition for our innovative products, especially Copaxone® (including competition from orally-administered alternatives, as well as from potential purported generic equivalents); the possibility of material fines, penalties and other sanctions and other adverse consequences arising out of our ongoing FCPA investigations and related matters; our ability to achieve expected results from the research and development efforts invested in our pipeline of specialty and other products; our ability to reduce operating expenses to the extent and during the timeframe intended by our cost reduction program; our ability to identify and successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; the extent to which any manufacturing or quality control problems damage our reputation for quality production and require costly remediation; our potential exposure to product liability claims that are not covered by insurance; increased government scrutiny in both the U.S. and Europe of our patent settlement agreements; our exposure to currency fluctuations and restrictions as well as credit risks; the effectiveness of our patents, confidentiality agreements and other measures to protect the intellectual property rights of our specialty medicine; the effects of reforms in healthcare regulation and pharmaceutical pricing, reimbursement and coverage; governmental investigations into sales and marketing practices, particularly for our specialty pharmaceutical products; uncertainties related to our recent management changes; the effects of increased leverage and our resulting reliance on access to the capital markets; any failure to recruit or retain key personnel, or to attract additional executive and managerial talent; adverse effects of political or economical instability, major hostilities or acts of terrorism on our significant worldwide operations; interruptions in our supply chain or problems with internal or third-party information technology systems that adversely affect our complex manufacturing processes; significant disruptions of our information technology systems or breaches of our data security; competition for our generic products, both from other pharmaceutical companies and as a result of increased governmental pricing pressures; competition for our specialty pharmaceutical businesses from companies with greater resources and capabilities; decreased opportunities to obtain U.S. market exclusivity for significant new generic products; potential liability in the U.S., Europe and other markets for sales of generic products prior to a final resolution of outstanding patent litigation; any failures to comply with complex Medicare and Medicaid reporting and payment obligations; the impact of continuing consolidation of our distributors and customers; significant impairment charges relating to intangible assets and goodwill; potentially significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; variations in patent laws that may adversely affect our ability to manufacture our products in the most efficient manner; environmental risks; and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2013 and in our other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and we assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Consolidated Statements of Income
(Unaudited, U.S. dollars in millions, except share and per share data)
Three months ended Six months ended
June 30, June 30,
2014 2013 2014 2013
Net revenues 5,045 4,924 10,046 9,825
Cost of sales 2,384 2,331 4,688 4,642
Gross profit 2,661 2,593 5,358 5,183
Research and development expenses 344 339 697 668
Selling and marketing expenses 921 982 1,905 1,977
General and administrative expenses 302 319 604 626
Legal settlements and loss contingencies 26 1,435 55 1,462
Impairments, restructuring and others 143 104 200 162
Operating income (loss) 925 (586) 1,897 288
Financial expenses - net 78 89 159 264
Income (loss) before income taxes 847 (675) 1,738 24
Income taxes 102 (222) 245 (169)
Share in losses of associated companies - net - 3 8 23
Net income (loss) 745 (456) 1,485 170
Net loss attributable to non-controlling interests (3) (4) (7) (8)
Net income (loss) attributable to Teva 748 (452) 1,492 178
Earnings (loss) per share attributable to Teva: Basic ($) 0.88 (0.53) 1.75 0.21
Diluted ($) 0.87 (0.53) 1.75 0.21
Weighted average number of shares (in millions): Basic 852 849 851 852
Diluted 857 849 855 853
Non-GAAP net income attributable to Teva:* 1,054 1,018 2,092 1,978
Non-GAAP earnings per share attributable to Teva: Basic ($) 1.24 1.20 2.46 2.32
Diluted ($) 1.23 1.20 2.45 2.32
Weighted average number of shares (in millions): Basic 852 849 851 852
Diluted 857 850 855 853
* See reconciliation attached.
Condensed Consolidated Balance Sheets
(U.S. dollars in millions)
(Unaudited)
June 30, December 31,
2014 2013
ASSETS
Current assets:
Cash and cash equivalents 949 1,038
Accounts receivable 5,389 5,338
Inventories 4,940 5,053
Deferred income taxes 1,066 1,084
Other current assets 1,202 1,207
Total current assets 13,546 13,720
Other non-current assets 1,469 1,696
Property, plant and equipment, net 6,709 6,635
Identifiable intangible assets, net 6,062 6,476
Goodwill 18,948 18,981
Total assets 46,734 47,508
LIABILITIES AND EQUITY
Current liabilities:
Short-term debt 2,048 1,804
Sales reserves and allowances 5,348 4,918
Accounts payable and accruals 3,026 3,317
Other current liabilities 1,432 1,926
Total current liabilities 11,854 11,965
Long-term liabilities:
Deferred income taxes 1,169 1,247
Other taxes and long-term liabilities 1,000 1,273
Senior notes and loans 9,122 10,387
Total long term liabilities 11,291 12,907
Equity:
Teva shareholders' equity 23,540 22,565
Non-controlling interests 49 71
Total equity 23,589 22,636
Total liabilities and equity 46,734 47,508
Condensed Consolidated Cash Flow
(Unaudited, U.S. Dollars in millions)
Three months ended Six months ended
June 30, June 30,
2014 2013 2014 2013
Operating activities:
Net income (loss) 745 (456 ) 1,485 170
Net change in operating assets and liabilities (89 ) 1,150 (337 ) 1,210
Items not involving cash flow 397 181 803 597
Net cash provided by operating activities 1,053 875 1,951 1,977
Net cash used in investing activities (187 ) (266 ) (575 ) (532 )
Net cash used in financing activities (819 ) (748 ) (1,453 ) (3,008 )
Translation adjustment on cash and cash equivalents 1 (10 ) (12 ) (71 )
Net change in cash and cash equivalents 48 (149 ) (89 ) (1,634 )
Balance of cash and cash equivalents at beginning of period 901 1,394 1,038 2,879
Balance of cash and cash equivalents at end of period 949 1,245 949 1,245
Non GAAP reconciliation items
(Unaudited, U.S. Dollars in millions)
Three months ended Six months ended
June 30, June 30,
2014 2013 2014 2013
Amortization of purchased intangible assets - under cost of sales 249 279 517 548
Restructuring and other expenses 87 55 143 98
Impairment of long-lived assets 56 49 57 64
Expense in connection with legal settlements and reserves 26 1,435 55 1,462
Costs related to regulatory actions taken in facilities - under cost of
sales
14 16 32 28
Amortization of purchased intangible assets - under selling and
marketing expenses
7 9 24 19
Accelerated Depreciation 3 - 7 -
Purchase of research and development in process - 3 - 3
Financial (income) expense 2 7 (1) 101
Tax benefit
(138) (383) (234) (523)
Reconciliation between reported Net Income attributable to Teva and Earnings per share as reported under US GAAP to Non-GAAP Net Income attributable to Teva and Earnings per share
Six months ended June 30, 2014 Six months ended June 30, 2013
U.S. dollars and shares in millions (except per share amounts)
GAAP
Non-GAAP
Adjustments
Non-
GAAP
% of Net
Revenues
GAAP
Non-GAAP
Adjustments
Non-
GAAP
% of Net
Revenues
Gross profit (1) 5,358 556 5,914 58.9 % 5,183 576 5,759 58.6 %
Operating income (1)(2) 1,897 835 2,732 27.2 % 288 2,222 2,510 25.5 %
Net income attributable to Teva (1)(2)(3) 1,492 600 2,092 20.8 % 178 1,800 1,978 20.1 %
Earnings per share attributable to Teva - Diluted (4) 1.75 0.70 2.45 0.21 2.11 2.32
(1 ) Amortization of purchased intangible assets 517 548
Costs related to regulatory actions taken in facilities 32 28
Accelerated depreciation 7 -
Gross profit adjustments 556 576
(2 ) Restructuring, acquisition and other expenses 143 101
Impairment of long-lived assets 57 64
Expense in connection with legal settlements and reserves 55 1,462
Amortization of purchased intangible assets 24 19
279 1,646
Operating profit adjustments 835 2,222
(3 ) Financial (income) expense (1 ) 101
Tax benefit (234 ) (523 )
Net income adjustments 600 1,800
(4 ) The weighted average number of shares was 855 and 853 million for the six months ended June 30, 2014 and 2013, respectively. Non-GAAP earnings per share can be reconciled with GAAP earnings per share by dividing each of the amounts included in footnotes 1-3 above by the applicable weighted average share number.
Reconciliation between reported Net Income attributable to Teva and Earnings per share as reported under US GAAP to Non-GAAP Net Income attributable to Teva and Earnings per share
Three months ended June 30, 2014 Three months ended June 30, 2013
U.S. dollars and shares in millions (except per share amounts)
GAAP
Non-GAAP
Adjustments
Non-GAAP
% of Net
Revenues
GAAP
Non-GAAP
Adjustments
Non-GAAP
% of Net
Revenues
Gross profit (1) 2,661 266 2,927 58.0 % 2,593 295 2,888 58.7 %
Operating income (loss) (1)(2) 925 442 1,367 27.1 % (586 ) 1,846 1,260 25.6 %
Net income (loss) attributable to Teva (1)(2)(3) 748 306 1,054 20.9 % (452 ) 1,470 1,018 20.7 %
Earnings (loss) per share attributable to Teva - Diluted (4) 0.87 0.36 1.23 (0.53 ) 1.73 1.20
(1 ) Amortization of purchased intangible assets 249 279
Costs related to regulatory actions taken in facilities 14 16
Accelerated depreciation 3 -
Gross profit adjustments 266 295
(2 ) Restructuring and other expenses 87 58
Impairment of long-lived assets 56 49
Expense in connection with legal settlements and reserves 26 1,435
Amortization of purchased intangible assets 7 9
176 1,551
Operating income adjustments 442 1,846
(3 ) Financial expense 2 7
Tax benefit (138 ) (383 )
Net income adjustments 306 1,470
(4 ) The weighted average number of shares was 857 million and 850 million for the three months ended June 30, 2014 and 2013, respectively. Non-GAAP earnings per share can be reconciled with GAAP earnings per share by dividing each of the amounts included in footnotes 1-3 above by the applicable weighted average share number.
Segment Information
Generics Specialty
Three months ended June 30,
Percentage Change
Three months ended June 30,
Percentage Change
2014 2013 2014 - 2013 2014 2013 2014 - 2013
U.S.$ in millions / % of Segment Revenues U.S.$ in millions / % of Segment Revenues
Revenues 2,515 100% 2,405 100% 5% 2,027 100% 2,051 100% (1%)
Gross Profit 1,046 41.6% 989 41.1% 6% 1,768 87.2% 1,772 86.4% §
R&D Expenses 126 5.0% 124 5.2% 2% 214 10.6% 208 10.1% 3%
S&M Expenses 388 15.4% 489 20.3% (21%) 484 23.9% 450 21.9% 8%
Segment Profitability* 532 21.2% 376 15.6% 41% 1,070 52.8% 1,114 54.3% (4%)
* Segment profitability consists of gross profit, less S&M and R&D expenses related to the segment. Segment profitability does not include G&A expenses, amortization and certain other items.
We recently changed the classification of certain of our products. The data presented has been conformed to reflect the revised classification for all periods.
§ Less than 0.5%.
Segment Information
Generics Specialty
Six months ended June 30,
Percentage Change
Six months ended June 30,
Percentage Change
2014 2013 2014 - 2013 2014 2013 2014 - 2013
U.S.$ in millions / % of Segment Revenues U.S.$ in millions / % of Segment Revenues
Revenues 4,913 100% 4,733 100% 4% 4,141 100% 4,103 100% 1%
Gross Profit 2,088 42.5% 1,940 41.0% 8% 3,611 87.2% 3,558 86.7% 1%
R&D Expenses 250 5.1% 232 4.9% 8% 441 10.6% 409 10.0% 8%
S&M Expenses 807 16.4% 950 20.1% (15%) 983 23.7% 903 22.0% 9%
Segment Profitability* 1,031 21.0% 758 16.0% 36% 2,187 52.8% 2,246 54.7% (3%)
* Segment profitability consists of gross profit, less S&M and R&D expenses related to the segment. Segment profitability does not include G&A expenses, amortization and certain other items.
We recently changed the classification of certain of our products. The data presented has been conformed to reflect the revised classification for all periods.
Additional Information
Multiple Sclerosis
Three months ended June 30, Percentage Change
2014 2013 2014 - 2013
U.S.$ in millions / % of MS Revenues
Revenues 939 100% 1,070 100% (12%)
Gross profit 840 89.5% 951 88.9% (12%)
R&D expenses 20 2.1% 20 1.9% §
S&M expenses 120 12.8% 130 12.1% (8%)
MS profitability 700 74.5% 801 74.9% (13%)
Other Specialty
Three months ended June 30, Percentage Change
2014 2013 2014 - 2013
U.S.$ in millions / % of Other Specialty Revenues
Revenues 1,088 100% 981 100% 11%
Gross profit 928 85.3% 821 83.7% 13%
R&D expenses 194 17.8% 188 19.2% 3%
S&M expenses 364 33.5% 320 32.6% 14%
Other Specialty profitability 370 34.0% 313 31.9% 18%
We recently changed the classification of certain of our products.
The data presented has been conformed to reflect the revised classification for all periods.
§ Less than 0.5%.
Additional information
Multiple Sclerosis
Six months ended June 30, Percentage Change
2014 2013 2014 - 2013
U.S.$ in millions / % of MS Revenues
Revenues $ 2,009 100% $ 2,134 100% (6%)
Gross profit 1,801 89.6% 1,907 89.4% (6%)
R&D expenses 42 2.1% 41 1.9% 2%
S&M expenses 285 14.2% 240 11.2% 19%
MS profitability 1,474 73.4% 1,626 76.2% (9%)
Other Specialty
Six months ended June 30, Percentage Change
2014 2013 2014 - 2013
U.S.$ in millions / % of Other Specialty Revenues
Revenues $ 2,132 100% $ 1,969 100% 8%
Gross profit 1,810 84.9% 1,651 83.8% 10%
R&D expenses 399 18.7% 368 18.7% 8%
S&M expenses 698 32.7% 663 33.7% 5%
Other Specialty profitability 713 33.4% 620 31.5% 15%
We recently changed the classification of certain of our products.
The data presented has been conformed to reflect the revised classification for all periods.
Reconciliation of our segment profitability to Teva's consolidated income before income taxes
Three months ended June 30,
2014 2013
U.S.$ in millions
Generic medicine profitability 532 376
Specialty medicine profitability 1,070 1,114
Total segment profitability 1,602 1,490
Profitability of other activities 67 89
Total profitability 1,669 1,579
Amounts not allocated to segments:
Amortization 256 288
General and administrative expenses 302 319
Legal settlements and loss contingencies 26 1435
Impairments, restructuring and others 143 104
Other unallocated amounts 17 19
Consolidated operating income (loss) 925 (586)
Financial expenses - net 78 89
Consolidated income (loss) before income taxes 847 (675)
Reconciliation of our segment profitability to Teva's consolidated income before income taxes
Six months ended June 30,
2014 2013
U.S.$ in millions
Generic medicines profitability 1,031 758
Specialty medicines profitability 2,187 2,246
Total segment profitability 3,218 3,004
Profitability of other activities 118 132
Total profitability 3,336 3,136
Amounts not allocated to segments:
Amortization 541 567
General and administrative expenses 604 626
Legal settlements and loss contingencies 55 1,462
Impairments, restructuring and others 200 162
Other unallocated amounts 39 31
Consolidated operating income 1,897 288
Financial expenses - net 159 264
Consolidated income before income taxes 1,738 24
Revenues by Activity and Geographical Area
(Unaudited)
Three Months Ended
June 30,
Percentage
Change
Percentage
Change
2014 2013 2014 - 2013 2014 - 2013
U.S. $ in millions
in local
currencies
Generic Medicine
United States $ 1,068 $ 967 10% 10%
Europe* 814 827 (2%) (6%)
Rest of the World. 633 611 4% 11%
Total Generic Medicine 2,515 2,405 5% 5%
Specialty Medicine
United States 1,419 1,497 (5%) (5%)
Europe* 501 443 13% 7%
Rest of the World. 107 111 (4%) 5%
Total Specialty Medicine 2,027 2,051 (1%) (2%)
Other Revenues
United States 50 58 (14%) (14%)
Europe* 206 187 10% 6%
Rest of the World. 247 223 11% 12%
Total Other Revenues 503 468 7% 6%
Total Revenues $ 5,045 $ 4,924 2% 2%
* All members of the European Union, Switzerland, Norway, Albania and the countries of former Yugoslavia.
We recently changed the classification of certain of our products.
The data presented has been conformed to reflect the revised classification for all periods.
Revenues by Activity and Geographical Area
(Unaudited)
Six Months Ended June 30,
Percentage
Change
Percentage
Change
2014 2013 2014 - 2013 2014 - 2013
U.S. $ in millions
in local
currencies
Generic Medicines
United States $ 2,116 $ 1,860 14% 14%
Europe* 1,632 1,676 (3%) (7%)
Rest of the World 1,165 1,197 (3%) 6%
Total Generic Medicines 4,913 4,733 4% 5%
Specialty Medicines
United States 2,949 2,977 (1%) (1%)
Europe* 983 891 10% 6%
Rest of the World 209 235 (11%) (2%)
Total Specialty 4,141 4,103 1% §
Other Revenues
United States 101 126 (20%) (20%)
Europe* 413 384 8% 5%
Rest of the World 478 479 § 2%
Total Other Revenues 992 989 § §
Total Revenues $ 10,046 $ 9,825 2% 2%
* All members of the European Union, Switzerland, Norway, Albania and the countries of former Yugoslavia.
We recently changed the classification of certain of our products.
The data presented has been conformed to reflect the revised classification for all periods.
§ Less than 0.5%.
Revenues by Product line
(Unaudited)
Three Months Ended
June 30,
Percentage
Change
2014 2013 2014 - 2013
U.S. $ in millions
Generic Medicine $ 2,515 $ 2,405 5%
API 182 190 (4%)
Specialty Medicine 2,027 2,051 (1%)
CNS 1,271 1,361 (7%)
Copaxone® 939 1,070 (12%)
Azilect® 103 87 18%
Nuvigil® 88 74 19%
Oncology 284 246 15%
Treanda® 190 177 7%
Respiratory 257 241 7%
ProAir® 133 115 16%
Qvar® 74 76 (3%)
Women's Health 128 118 8%
Other Specialty 87 85 2%
All Others 503 468 7%
OTC 274 257 7%
Other Revenues 229 211 9%
Total $ 5,045 $ 4,924 2%
We recently changed the classification of certain of our products.
The data presented has been conformed to reflect the revised classification for all periods.
Revenues by Product line
(Unaudited)
Six Months Ended
June 30,
Percentage
Change
2014 2013 2014 - 2013
U.S. $ in millions
Generic Medicines $ 4,913 $ 4,733 4%
API 361 382 (5%)
Specialty Medicines 4,141 4,103 1%
CNS 2,684 2,720 (1%)
Copaxone® 2,009 2,134 (6%)
Azilect® 217 180 21%
Nuvigil® 189 157 20%
Oncology 546 485 13%
Treanda® 370 348 6%
Respiratory 487 475 3%
ProAir® 247 203 22%
Qvar® 145 170 (15%)
Women's Health 252 242 4%
Other Specialty 172 181 (5%)
All Others 992 989 §
OTC 543 563 (4%)
Other Revenues 449 426 5%
Total $ 10,046 $ 9,825 2%
We recently changed the classification of certain of our products.
The data presented has been conformed to reflect the revised classification for all periods.
§ Less than 0.5%.
Source: Teva Pharmaceutical Industries Ltd.
Teva
IR:
United States
Kevin C. Mannix, 215-591-8912
or
Ran Meir, 215-591-3033
or
Israel
Tomer Amitai, 972 (3) 926-7656
or
PR:
Israel
Iris Beck Codner, 972 (3) 926-7246
or
United States
Denise Bradley, 215-591-8974